Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro.

Yaz G., Kabadere S., Oztopcu P., Durmaz R., Uyar R.

American journal of clinical oncology, vol.27, no.4, pp.384-8, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 4
  • Publication Date: 2004
  • Doi Number: 10.1097/01.coc.0000071945.15623.c6
  • Journal Name: American journal of clinical oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.384-8
  • Keywords: glioma, tamoxifen, nafoxidine, clomiphene, MTT assay, cell proliferation, PROTEIN-KINASE-C, INDUCE APOPTOSIS, BREAST-CANCER, TAMOXIFEN, MICROCULTURE, INVOLVEMENT, RECEPTOR, BINDING, TUMORS, GROWTH
  • Eskisehir Osmangazi University Affiliated: Yes


The antitumoral activity of nonsteroidal antiestrogens on C6 and low passage of human glioma cells was investigated. Tamoxifen and its metabolite, 4-hydroxytamoxifen, did not influence viability of the human cells, but tamoxifen had a limited antiproliferative effect on C6 cells (IC50: 49 mumol/l). The derivatives of tamoxifen, nafoxidine and clomiphene, caused reduction of living cell number in a dose-dependent manner. These two drugs showed differences in their potency following 24-hour incubation in a humidified atmosphere with 37degreesC and 5% CO2. Obtained from a tetrazolium-formazan growth rate assay, IC50 of nafoxidine for C6 cells was calculated as 44 mumol/l and for the human cells as 16.5 mumol/l. The calculated IC50 dose of clomiphene for C6 is 16 mumol/l and for the human cells 13 mumol/l. Compared to the other drugs we used, it is clear that clomiphene is the most efficient inhibitor of C6 and the human glioma cells. These preliminary results suggest that nafoxidine and clomiphene possess antiproliferative effect on two different sources of glioma cells and therefore, instead of tamoxifen, multiple activities of these drugs may enable their use in combination therapy of glioblastoma malignancies.